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Abstract: 
The historical under-representation of Blacks in clinical trials is well-documented. The ethical ramifications of racial under-
representation in clinical trials are exacerbated by the epidemiologic and clinical consequences. For example, persistent under-
representation undermines generalizability and challenges inferences regarding treatment safety and efficacy for minority races. The 
potential for such consequences warrants greater racial diversity in clinical trials. However, investigators have assumed that 
recruiting Blacks for clinical trials is hampered by unwillingness to participate. Recent reports indicate that the perception of 
unwillingness may be unjustified. An often overlooked aspect is that conventional recruitment strategies may be ineffective for 
recruiting racial minorities. Public health professionals from all disciplines have the collective capacity to improve racial diversity in 
clinical trials primarily because of access to minority communities. Public health professionals could facilitate an effort to encourage 
collaboration between trial centers and community health clinics in predominantly minority settings. 
 
 
The historical under-representation of Blacks in 
clinical trials is well-documented.[1-10] Concerns of 
racial (and gender) under-representation led to the 
development of the National Institutes of Health (NIH) 
Revitalization Act of 1993 that incorporated guidelines 
on the inclusion of racial minorities as participants in 
clinical research.[11] The guidelines were intended to 
create awareness of minority under-representation and 
promote diverse participation. The NIH’s recognition 
and action regarding disparate racial representation is 
ethically and scientifically mindful. Currently, NIH-
funded trials are ~2.4 times more likely (55.8% vs. 
23.7%, p<0.001) than non-NIH funded trials to report 
racial characteristics.[4] The emphasis on greater 
accountability resulted in improved racial diversity, but 
the improvement is inadequate. Although statistical 
significance may have been achieved because the study 
utilized a large sample size, NIH-funded trials are only 
somewhat more likely than non NIH-funded trials to 
include racial minorities (13.5% vs. 12.5%, p<0.001).[4] 
The ethical ramifications of racial under-
representation in clinical trials are exacerbated by the 
epidemiologic and clinical consequences. Persistent 
under-representation undermines generalizability and 
challenges inferences regarding treatment safety and 
efficacy for minority races.[1-3,5,7,10,12] For example, 
recent evidence indicated that statin use prior to 
ischemic stroke incidence may be beneficial for 
preventing poor stroke outcomes among Whites, but 
statin pretreatment may be detrimental for Blacks.[13] 
The overall estimate suggested lower odds of poor 
outcomes among statin pretreated patients (OR=0.74, 
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95% CI 0.53, 1.02), but the race-specific estimates were 
markedly different on a multiplicative scale (Whites: 
OR=0.61, 95% CI 0.42, 0.86; Blacks: OR=1.82, 95% CI 
0.98, 3.39).[13] Interestingly, the overall estimate in the 
investigation by Reeves et al. corroborated results from 
the landmark Stroke Prevention by Aggressive 
Reduction in Cholesterol Levels (SPARCL) trial.[14] 
However, the SPARCL investigators did not report racial 
characteristics of the study population or race-specific 
effect estimates. Stratified analyses would be justifiably 
avoided if Blacks were under-represented in the trial 
because sparse data yield unstable effect estimates, but 
the potential for differential treatment response 
between races reiterates the necessity for incorporating 
a sufficient number of minorities in clinical trials. 
Sufficient racial representation may allow for improved 
evaluation of race-specific effects. 
The scientific community’s justification for 
insufficient racial representation is, perhaps, the 
greatest concern. Investigators have assumed that 
recruiting Blacks for clinical trials is hampered by 
unwillingness to participate.[1,15] The Black 
community’s mistrust resulting from unethical events in 
medical history is most often cited as the underlying 
reason for unwillingness to participate in current 
research.[1,15] However, recent reports, including a 
systematic review, indicate that the perception of 
unwillingness may be unjustified.[1,2,16] The sample of 
clinical trials identified by Wendler et al. yielded greater 
consent rates for Blacks than Non-Hispanic Whites 
(45.3% vs. 41.8%).[1] Blacks also demonstrated higher 
consent rates than Non-Hispanic Whites for surgical 
interventions (65.8% vs. 47.8%).[1] A separate 
investigation reported that willingness to participate in 
HIV vaccine trials was not associated with race despite a 
higher prevalence of general mistrust among racial 
minorities.[16] The emerging evidence indicates an 
unsettling disconnect between the perceptions of the 
scientific community and the reality regarding the 
willingness of Blacks to participate in clinical trials. 
Furthermore, the reports raise concerns that current 
approaches to minority recruitment for clinical research 
may be ineffective.[1,16] 
Public health professionals from all disciplines 
have the collective capacity to improve racial diversity 
in clinical trials primarily because of access to minority 
communities. For example, public health professionals 
could facilitate an effort to encourage collaboration 
between trial centers and community health clinics in 
predominantly minority settings. Community health 
clinics may be a valuable resource for recruiting racial 
minorities because of familiarity with the population. 
Efforts to inform community clinics of upcoming clinical 
trials and sustain access to information for providers 
and potential participants may gradually improve 
minority recruitment. Furthermore, mistrust may be 
reduced by involving community clinics. Minority 
populations may be more receptive to information and 
education regarding clinical trials from trusted providers 
rather than trial centers without pre-existing 
involvement in the community.[17,18] Community 
providers may also be more capable of providing 
pertinent information in a culturally sensitive 
manner.[17,18] 
A comprehensive strategy based on some of the 
principles outlined herein was successful in recruiting 
and enrolling racial minorities for the Women’s Health 
Initiative (WHI) trial and may serve as a practical 
model.[18] For example, non-minority women were 
more effectively recruited by mass mailings and 
presentations at community-based events, whereas 
minority women were more effectively recruited using 
referral programs and presentations at churches 
supplemented with mass mailings.[18] Black women 
who received the trial information had the lowest 
refusal rates compared to other races,[18] a 
phenomenon expanded to include all Blacks by Wendler 
et al.[1] Therefore, a critical issue may be simply 
ensuring that Blacks and other racial minorities receive 
the appropriate information.[18] Ultimately, mounting 
evidence indicates that conventional recruitment 
strategies may be limited by a lack of generalizability to 
other races, similar to the results from some clinical 
trials. 
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